I
Invivyd
Developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses
About Invivyd
Adagio Therapeutics, operating under the brand name Invivyd, is a biotechnology startup focused on the development and delivery of antibody-based therapies to combat viral threats. The company's primary target market includes individuals with weakened immune systems who may not receive adequate protection from traditional vaccinations, such as those who are immunocompromised.
Read full description
Invivyd's business model revolves around leveraging advanced technologies like viral surveillance, predictive modeling, and antibody engineering to continuously discover and optimize monoclonal antibody candidates. These candidates are designed to protect vulnerable populations from serious viral threats, starting with COVID-19 and potentially expanding to influenza and other high-need indications.
The company's lead candidate, VYD222, is currently in development for the prevention of symptomatic COVID-19 in vulnerable populations, including solid organ and stem cell transplant recipients and individuals with blood cancers.
Invivyd's revenue generation strategy is likely based on the successful development, approval, and commercialization of its antibody therapies. The company may also generate income through strategic partnerships, licensing agreements, and government grants or contracts.
In summary, Invivyd is a forward-thinking biotech startup with a mission to protect the most vulnerable from evolving viral threats through the development of innovative antibody-based therapies.
Latest news
Press, funding announcements and product moves mentioning Invivyd.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Polaris Partners
Mithril
GV
Fidelity Investments
Omega Funds
Series B and later10 investors entered at this stage
RA Capital Management
OrbiMed
ArrowMark Partners
Population Health Partners
Premji Invest
Foresite Capital
Adimab
Redmile Group
Federated Hermes
Silicon Valley Bank
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
5 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Invivyd on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Invivyd on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.